Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1311629rdf:typepubmed:Citationlld:pubmed
pubmed-article:1311629lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:1311629lifeskim:mentionsumls-concept:C0007589lld:lifeskim
pubmed-article:1311629lifeskim:mentionsumls-concept:C0007102lld:lifeskim
pubmed-article:1311629lifeskim:mentionsumls-concept:C0334227lld:lifeskim
pubmed-article:1311629lifeskim:mentionsumls-concept:C0596138lld:lifeskim
pubmed-article:1311629lifeskim:mentionsumls-concept:C0021665lld:lifeskim
pubmed-article:1311629lifeskim:mentionsumls-concept:C1704735lld:lifeskim
pubmed-article:1311629lifeskim:mentionsumls-concept:C1511941lld:lifeskim
pubmed-article:1311629pubmed:issue1lld:pubmed
pubmed-article:1311629pubmed:dateCreated1992-4-6lld:pubmed
pubmed-article:1311629pubmed:abstractTextThe polyanionic compound suramin triggers enterocyte-like differentiation of the human colic adenocarcinoma cell clone HT29-D4. We now demonstrate that suramin interferes with the binding of IGF-I to its receptor at the surface of HT29-D4 cells. Half-maximum inhibition of 125I-IGF-I binding was obtained in the presence of 25 micrograms/ml suramin. Moreover, the drug was able to dissociate 125I-IGF previously bound to its cell surface receptor. Affinity labeling HT29-D4 cells were cultured in the presence of 10 micrograms/ml of alpha-IR3, a monoclonal antibody directed against the binding site of IGF-I, an inhibition of cell proliferation and a stimulation of cell differentiation was observed. After 10 days of treatment with alpha-IR3, HT29-D4 cells formed a regular monolayer of enterocyte-like cells exhibiting an apical brush border and tight junctions delimiting two domains of the plasma membrane (apical and basolateral). Furthermore, we show that IGF-I significantly increased the initial rate of glucose uptake by HT29-D4 cells, while we have previously shown that suramin decreased glucose consumption. From these data we conclude that IGF-I secreted by the cells themselves, stimulates proliferation of HT29-D4 cells via an autocrine mechanism. Blockade of this stimulation by suramin or by a specific monoclonal antibody inhibits cell growth, glucose uptake and triggers the process of enterocytic differentiation.lld:pubmed
pubmed-article:1311629pubmed:languageenglld:pubmed
pubmed-article:1311629pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1311629pubmed:citationSubsetIMlld:pubmed
pubmed-article:1311629pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1311629pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1311629pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1311629pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1311629pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1311629pubmed:statusMEDLINElld:pubmed
pubmed-article:1311629pubmed:monthFeblld:pubmed
pubmed-article:1311629pubmed:issn0304-3835lld:pubmed
pubmed-article:1311629pubmed:authorpubmed-author:VerrierBBlld:pubmed
pubmed-article:1311629pubmed:authorpubmed-author:GerardCClld:pubmed
pubmed-article:1311629pubmed:authorpubmed-author:FantiniJJlld:pubmed
pubmed-article:1311629pubmed:authorpubmed-author:BaghdiguianSSlld:pubmed
pubmed-article:1311629pubmed:issnTypePrintlld:pubmed
pubmed-article:1311629pubmed:day14lld:pubmed
pubmed-article:1311629pubmed:volume62lld:pubmed
pubmed-article:1311629pubmed:ownerNLMlld:pubmed
pubmed-article:1311629pubmed:authorsCompleteYlld:pubmed
pubmed-article:1311629pubmed:pagination23-33lld:pubmed
pubmed-article:1311629pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:1311629pubmed:meshHeadingpubmed-meshheading:1311629-...lld:pubmed
pubmed-article:1311629pubmed:meshHeadingpubmed-meshheading:1311629-...lld:pubmed
pubmed-article:1311629pubmed:meshHeadingpubmed-meshheading:1311629-...lld:pubmed
pubmed-article:1311629pubmed:meshHeadingpubmed-meshheading:1311629-...lld:pubmed
pubmed-article:1311629pubmed:meshHeadingpubmed-meshheading:1311629-...lld:pubmed
pubmed-article:1311629pubmed:meshHeadingpubmed-meshheading:1311629-...lld:pubmed
pubmed-article:1311629pubmed:meshHeadingpubmed-meshheading:1311629-...lld:pubmed
pubmed-article:1311629pubmed:meshHeadingpubmed-meshheading:1311629-...lld:pubmed
pubmed-article:1311629pubmed:meshHeadingpubmed-meshheading:1311629-...lld:pubmed
pubmed-article:1311629pubmed:meshHeadingpubmed-meshheading:1311629-...lld:pubmed
pubmed-article:1311629pubmed:meshHeadingpubmed-meshheading:1311629-...lld:pubmed
pubmed-article:1311629pubmed:meshHeadingpubmed-meshheading:1311629-...lld:pubmed
pubmed-article:1311629pubmed:meshHeadingpubmed-meshheading:1311629-...lld:pubmed
pubmed-article:1311629pubmed:year1992lld:pubmed
pubmed-article:1311629pubmed:articleTitleInsulin like growth factor I is an autocrine regulator of human colon cancer cell differentiation and growth.lld:pubmed
pubmed-article:1311629pubmed:affiliationINSERM U270, Faculté de Médecine, Marseille, France.lld:pubmed
pubmed-article:1311629pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1311629pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1311629lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1311629lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1311629lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1311629lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1311629lld:pubmed